Company Overview
| Stock Name | Yzybio-B |
|---|---|
| Stock Code | 02496 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家致力于開發用于治療癌癥相關并發癥、癌癥及老年性眼科疾病的BsAb療法的生物技術公司。 |
| Listing Date | 2023-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.yzybio.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 59.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 17,603,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,200 |
| 2 lots | 400 | HK$ 6,400 |
| 3 lots | 600 | HK$ 9,600 |
| 4 lots | 800 | HK$ 12,800 |
| 5 lots | 1,000 | HK$ 16,000 |
| 6 lots | 1,200 | HK$ 19,200 |
| 7 lots | 1,400 | HK$ 22,400 |
| 8 lots | 1,600 | HK$ 25,600 |
| 9 lots | 1,800 | HK$ 28,800 |
| 10 lots | 2,000 | HK$ 32,000 |
| 15 lots | 3,000 | HK$ 48,000 |
| 20 lots | 4,000 | HK$ 64,000 |
| 25 lots | 5,000 | HK$ 80,000 |
| 30 lots | 6,000 | HK$ 96,000 |
| 35 lots | 7,000 | HK$ 112,000 |
| 40 lots | 8,000 | HK$ 128,000 |
| 45 lots | 9,000 | HK$ 144,000 |
| 50 lots | 10,000 | HK$ 160,000 |
| 75 lots | 15,000 | HK$ 240,000 |
| 100 lots | 20,000 | HK$ 320,000 |
| 125 lots | 25,000 | HK$ 400,000 |
| 150 lots | 30,000 | HK$ 480,000 |
| 175 lots | 35,000 | HK$ 560,000 |
| 200 lots | 40,000 | HK$ 640,000 |
| 250 lots | 50,000 | HK$ 800,000 |
| 300 lots | 60,000 | HK$ 960,000 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 16.0 |
|---|---|
| First Day Open | HK$ 16.4 |
| First Day Change | -67.75% |
| First Day Volume | 1519600.0 |
| First Day Turnover | 24912300.0 |
Use of Proceeds
| Use of Proceeds | 1、約80%或約97.1百萬港元將用作核心產品M701計劃進行的臨床試驗、擬備注冊備案文件及商業化推出計劃； 2、約12%或14.6百萬港元將用作Y101D計劃進行的臨床試驗； 3、約8%或9.7百萬港元將用作營運資金和一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
China Securities (International) Corporate Finance Company Limited CE BAU112
Overall Coordinators (3)
Joint Bookrunners (6)
China Securities (International) Corporate Finance Company Limited CE BAU112
GUOTAI JUNAN SECURITIES (HONG KONG) LIMITED CE ABY236
CCB International Capital Limited CE AJO225
BOCI ASIA LIMITED CE AET863
TFI Securities and Futures Limited CE BAV573
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
Joint Lead Managers (8)
China Securities (International) Corporate Finance Company Limited CE BAU112
GUOTAI JUNAN SECURITIES (HONG KONG) LIMITED CE ABY236
CCB International Capital Limited CE AJO225
BOCI ASIA LIMITED CE AET863
TFI Securities and Futures Limited CE BAV573
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
Livermore Holdings Limited CE BJN764
Futu Securities International (Hong Kong) Limited CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 成都朴华凯智生物科技有限公司 | 21,481,600 HKD | — | 12.20% | — | 6 months | 2024-03-25 |
| 2 | 武汉光谷健康产业投资有限公司 | 42,976,000 HKD | — | 24.42% | — | 6 months | 2024-03-25 |
| 3 | 武汉市楚兴友瑞大健康产业投资基金合伙企业(有限合伙) | 39,763,200 HKD | — | 22.59% | — | 6 months | 2024-03-25 |
Directors & Management
| Chairman | Zhou Pengfei |
|---|---|
| Company Secretary | 鄭建華;賴天恩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 袁謙(10.57%);武漢才智投資管理合伙企業(有限合伙)(8.70%);周宏峰(5.28%) |
|---|
